SUPN SUPERNUS PHARMACEUTICALS, INC. Insider Trading

Sr. VP sells 107,250 SUPN shares (86.3% of holdings) for $5.4M across three days at $50.24 avg; 100% prior sell timing record.

Bhatt executed 6 separate sales totaling 107,250 shares for $5,388,431.52 across March 16–18, 2026, reducing his holdings from 124,294 to 17,044 shares—a 86.3% reduction. This represents a substantial liquidation by a senior executive (Sr. VP of IP, CSO). His cross-ticker track record shows 5 prior sells with an average 90-day return of -19.3% and a 90-day well-timed rate of 100.00%, meaning all prior open-market sales preceded stock declines. At SUPN specifically, his 5 prior trades show identical 100% well-timing at the 90-day mark, with negative 90-day returns ranging from -13.5% to -24.5%. The company is unprofitable (net income -$45.1M) despite 8.6% annual revenue growth, and the stock has already declined 3.0% in the 30 days since these sales. The combination of near-complete position liquidation by an executive with a perfect record of well-timed exits at this ticker warrants attention to subsequent share price performance and company fundamentals.

CEO Khattar Jack A. sold 35,000 shares ($1.8M) across 3 transactions at blended $50.37; retains 958.1K shares at a $2.9B unprofitable biotech.

CEO Khattar Jack A. executed 3 separate sales totaling 35,000 shares for $1,763,124.42 on 2026-03-13, reducing his holdings by 3.5% to 958.1K shares. The transaction occurred near the 52-week high range (current price $50.21 is -11.9% from the $57.00 peak), and the blended sale price of $50.37 is above today's market. At SUPN specifically, his 5 prior sells show mixed timing results with only 1 of 5 well-timed at the 90-day horizon; his cross-ticker track record across 13 prior sells posted 90-day returns averaging +11.6% with a 15.38% well-timed rate, indicating his sells have typically been poorly timed overall as the stock rose afterward. The company reported quarterly revenue of $192,103,000.00 and net income of $-45,117,000.00, reflecting ongoing unprofitability despite +8.6% annual revenue growth. The sale's materiality and the company's negative earnings merit attention to whether this reflects portfolio management or signals on the CEO's confidence in near-term prospects.

SUPN SVP Frank Mottola sold 20,000 shares (56.3% of holdings) in 2 transactions for $1,008,150.00 at $50.41 avg.

Frank Mottola, Chief Technology Operations Officer, executed two separate sales totaling 20,000 shares for $1,008,150.00 on 2025-12-19, reducing his holdings from 35,496 shares to 15,496 shares. The blended sale price of $50.41 occurred when the stock was trading at $51.50 (current price), placing the transaction modestly below recent market levels. The company reported net income of $-45,117,000.00 against revenue of $192,103,000.00 in the latest quarter, indicating significant operational losses despite 8.9% annual revenue growth. This substantial reduction in an executive's position—eliminating 56.3% of his pre-transaction holdings—in a loss-making environment warrants investor attention to underlying operational or capital allocation concerns.

Director Charles W Newhall III sold 25,000 shares (19.3% of holdings) at blended avg $50.77 vs current price $49.00

Director Newhall executed 2 separate sales totaling 25,000 shares for $1,269,234.00 on 2025-10-09, reducing his holdings from 129.6K to 104.6K shares. The blended average price of $50.77 sits modestly above the current price of $49.00, and the stock has climbed 48.0% over 90 days, suggesting the director sold into strength. The company reports solid fundamentals with annual revenue growth of 8.9%, net income of $22.5M, and recent quarterly revenue of $165.5M, though the P/E of 42.61 reflects a premium valuation. This transaction represents a material 19.3% reduction in his direct holdings, though without a multi-executive context or prior pattern at this ticker, the filing stands as a single director's discretionary decision.

SUPN CEO Jack Khattar sells 59,900 shares (4.7% of holdings) for $3.0M on 2025-10-09; stock +6.0% in 30 days since sale

Jack Khattar, President and CEO of SUPERNUS PHARMACEUTICALS (SUPN), executed 2 separate sales totaling 59,900 shares for $3,029,336.39 ($3.0M) at a blended average price of $50.57 on 2025-10-09, reducing his holdings from 1,266,478 to 1,206,578 shares. This represents a -4.7% reduction in his position. Post-transaction, the stock has appreciated +6.0% over 30 days and +48.0% over 90 days from the filing date, moving from the $50.57 sale price toward the current $49.00 mark in context of a 52-week range of $30.29–$49.51. At the same-ticker level, Khattar has executed 5 prior sales at SUPN since 2025-08-28, with recent measurable outcomes showing +5.1% and +4.2% 30-day returns after those trades; his cross-ticker track record shows 11 prior sells with a 0.00% 90-day well-timed rate, indicating his sells historically did not precede stock declines. The company reports strong fundamentals with $165.5M quarterly revenue, $22.5M net income, +8.9% annual revenue growth, and a P/E of 42.61.

SUPN CEO Khattar sold 40,173 shares at $48.07 for $1,931,116.11, retaining 1,160,870 shares post-sale

Khattar Jack A., President and CEO, executed a sale of 40,173 shares at $48.07 on 2025-10-01, representing a -3.3% reduction from his pre-transaction holdings of 1,201,043 shares. The sale occurred near the 52-week high of $48.04 at a price of $47.96 current, suggesting the transaction was executed during a strong recovery period (stock up 7.7% over 30 days and up 50.0% over 90 days). His cross-ticker track record shows a 0.00% well-timed rate on prior sells across all tickers, indicating his prior open-market sales were not early indicators of stock declines. At SUPN specifically, his 5 prior trades all occurred in late August and early September, with recent outcomes showing modest 30-day gains (+4.2%, +4.4%) on the earlier September sales. The company maintains solid fundamentals with $165,453,000.00 in latest-quarter revenue, $22,499,000.00 in net income, and +8.9% annual revenue growth, though the P/E of 41.70 indicates elevated valuation expectations.

SUPN CEO Jack A. Khattar sold 29,513 shares at $47.23 on 2025-09-23 for $1.4M; retains 1.14M shares.

Jack A. Khattar (President, CEO) sold 29,513 shares at $47.23, representing 2.5% of his pre-transaction holdings of 1.17M shares. The sale occurred at the 52-week high ($47.10 current price, +0.0% from 52-week high), and the stock has gained 6.0% over 30 days and 51.0% over 90 days from the transaction date. Across his cross-ticker open-market history, Khattar's 9 prior sells averaged 90-day returns of +7.3%, with a 0.00% well-timed rate—indicating his past sells have consistently occurred before subsequent gains rather than before declines. At SUPN specifically, his 5 prior trades show only one with measurable 30-day outcome (+6.7%), and no completed 90-day outcomes to assess. The company shows solid fundamentals with $165.5M quarterly revenue, $22.5M net income, and +8.9% annual revenue growth, though the P/E of 40.96 reflects a premium valuation.

SUPN CEO Jack Khattar sold 16,587 shares at $47.02; stock +49.9% in 90 days while he has executed 5 consecutive sells.

CEO Khattar sold 16,587 shares (16.6K shares) at $47.02 on 2025-09-22, reducing his post-transaction holdings to 1,122,456 shares (1.12M shares). This represents the fifth consecutive sale at SUPN within approximately seven weeks, suggesting sustained liquidation activity during a period of notable momentum: the stock is up 49.9% over 90 days and up 4.3% over 30 days, trading near its 52-week high of $46.98. Against strong fundamental metrics (revenue $165.5M, net income $22.5M, +8.9% annual growth), the pattern of multiple dispositions warrants attention to whether this reflects portfolio rebalancing or structural conviction changes. His cross-ticker track record shows 9 prior sells with avg 90d return +7.3%, indicating his prior sells occurred before stocks rose—a poorly-timed pattern—though none of his five SUPN sales have reached measurable 90-day outcomes yet.

CEO Khattar Jack A. sold 55,578 shares of SUPN at $46.01, reducing holdings to 1,110,231 shares; stock up 11.1% in 30 days.

CEO Jack A. Khattar executed a $2.6M sale of 55,578 shares at $46.01, a price within 0.4% of the 52-week high, while the stock has risen 11.1% over 30 days and 37.8% over 90 days. His prior sales at SUPN (five trades since August 6) have not produced a single well-timed outcome at the 90-day mark, and his cross-ticker track record shows a 0.00% well-timed rate on prior sells, with a positive 7.3% average 90-day return suggesting his sales historically precede further gains. The company has strong fundamentals with $165.5M in quarterly revenue, $22.5M net income, and 8.9% annual growth, though the P/E of 39.84 indicates elevated valuation. This sale near a 52-week peak during a strong rally, combined with the insider's consistent pattern of selling into gains across multiple tickers, warrants attention to whether the stock's momentum can sustain.

SUPN CEO Khattar sells 34,800 shares for $1,569,430.50 across two days as stock rallies 34.4% in 30 days

Khattar Jack A., President and CEO of Supernus Pharmaceuticals, filed two separate sales totaling 34,800 shares for $1,569,430.50 on 2025-08-27 and 2025-08-28 at a blended average price of $45.10. The timing occurs during a pronounced rally: the stock is up 34.4% over 30 days and 42.3% over 90 days, now trading near its 52-week high of $45.37. Across his prior open-market sales activity, Khattar's 90-day well-timed rate is 0.00%, meaning his past sells have consistently been followed by stock appreciation rather than declines. At the same ticker, his 2 prior measurable sales (November 2024) saw post-sale returns of +2.4% and +1.3% at 30 days, +7.0% and +7.6% at 90 days—further evidence that Khattar's sale timing has not capitalized on subsequent downturns. The transaction reduces his holdings by 3.1% (from 1,127,433 to 1,092,633 shares), leaving him with substantial remaining exposure. This sale arrives amid a strong fundamental backdrop: the company reported revenue of $165,453,000.00 and net income of $22,499,000.00 in the latest quarter, with annual revenue growth of 8.9% and a P/E of 39.23.